Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

Guillermo Garcia-Manero, MD, Valeria Santini, MD, Antonio Almeida, MD PhD, Pierre Fenaux, MD PhD, Norbert Gatterman, MD PhD, Keiya Ozawa, MD PhD, Stuart L. Goldberg, MD, Jerry Weaver, PhD, Mary M. Sugrue, MD PhD

Blood (2016) 128 (22): 3190.

https://doi.org/10.1182/blood.V128.22.3190.3190

Published: 2016

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

David P. Steensma, MD, Bart L Scott, MD, Xiaomei Ma, PhD, Albert Fliss, PhD, Pavel Kiselev, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD

Blood (2016) 128 (22): 4768.

https://doi.org/10.1182/blood.V128.22.4768.4768

Published: 2016

Journal Articles

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Aaron T. Gerds, MD MS, Alan F. List, MD, Aristoteles Giagounidis, MD PhD, Eva Hellström-Lindberg, MD PhD, Jack Shiansong Li, PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Pierre Fenaux, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2867.

https://doi.org/10.1182/blood.V126.23.2867.2867

Published: 2015

Journal Articles

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Mikkael A. Sekeres, MD MS, Arlene S. Swern, PhD, Alan F. List, MD, Pierre Fenaux, MD PhD, Mary M. Sugrue, MD PhD

Blood (2015) 126 (23): 2870.

https://doi.org/10.1182/blood.V126.23.2870.2870

Published: 2015

Journal Articles

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

Xiaomei Ma, PhD, Arlene S. Swern, PhD, Pavel Kiselev, PhD, Albert Fliss, PhD, Jane J. Lu, MS, Bart L. Scott, MD, David P. Steensma, MD, Mary M. Sugrue, MD PhD

Blood (2015) 126 (23): 3319.

https://doi.org/10.1182/blood.V126.23.3319.3319

Published: 2015

Journal Articles

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Leonie Saft, MD PhD, Jack Shiansong Li, PhD, Peter L. Greenberg, MD PhD, Mikkael A. Sekeres, MD MS, Guillermo F. Sanz, MD PhD, François Dreyfus, MD, Pierre Fenaux, MD PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2014) 124 (21): 414.

https://doi.org/10.1182/blood.V124.21.414.414

Published: 2014

Journal Articles

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Lilia Weiss, MD, Dianna Gary, BSN, RN, Arlene S. Swern, PhD, John Freeman, MD, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 2975.

https://doi.org/10.1182/blood.V122.21.2975.2975

Published: 2013

Journal Articles

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Mikkael A. Sekeres, MD, MS, Arlene S. Swern, PhD, Aristoteles Giagounidis, MD, PhD, Alan List, MD, Brigitte Schlegelberger, MD, PhD, Pierre Fenaux, MD, PhD, Jack Shiansong Li, Mary M. Sugrue, MD, PhD

Blood (2013) 122 (21): 390.

https://doi.org/10.1182/blood.V122.21.390.390

Published: 2013

NARROW

Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Undertreatment of Patients (Pts) with Myelodysplastic Syndromes (MDS): Analysis of a Large Electronic Medical Records (EMR) Database Cohort of US Pts with MDS

Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q)

Use of an Electronic Medical Record (EMR) Database to Identify a Real-World Cohort of US Patients (Pts) with Myelodysplastic Syndromes (MDS)

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Real-World Analysis Of Celgene Global Drug Safety (GDS) Database: Early Permanent Discontinuation (D/C) Of Lenalidomide (LEN) In Patients (Pts) With Myelodysplastic Syndromes (MDS) Due To Nonserious (NS) Rash

Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only